KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gilead Sciences (GILD) Operating Income (2016 - 2025)

Gilead Sciences (GILD) has disclosed Operating Income for 17 consecutive years, with $2.0 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Income fell 19.09% year-over-year to $2.0 billion, compared with a TTM value of $10.0 billion through Dec 2025, up 503.01%, and an annual FY2025 reading of $10.0 billion, up 503.01% over the prior year.
  • Operating Income was $2.0 billion for Q4 2025 at Gilead Sciences, down from $3.3 billion in the prior quarter.
  • Across five years, Operating Income topped out at $3.8 billion in Q3 2021 and bottomed at -$4.3 billion in Q1 2024.
  • Average Operating Income over 5 years is $1.8 billion, with a median of $2.2 billion recorded in 2021.
  • The sharpest move saw Operating Income skyrocketed 765.48% in 2023, then plummeted 353.49% in 2024.
  • Year by year, Operating Income stood at $940.0 million in 2021, then skyrocketed by 141.17% to $2.3 billion in 2022, then decreased by 28.89% to $1.6 billion in 2023, then surged by 52.11% to $2.5 billion in 2024, then decreased by 19.09% to $2.0 billion in 2025.
  • Business Quant data shows Operating Income for GILD at $2.0 billion in Q4 2025, $3.3 billion in Q3 2025, and $2.5 billion in Q2 2025.